AI-generated summaries. Verify every claim with the cited sources before acting on them. Read our methodology

← Back to all reports

Galactosemia

Recent research efforts aimed at curing Galactosemia.

Last updated
Also available in
Français — Galactosémie

Galactosemia

Overview

Galactosemia is a group of inherited disorders in which the body cannot properly process galactose, a sugar released when lactose in milk is digested. This report focuses on classic galactosemia (CG), the severe and best-studied form, caused by very low or absent activity of galactose-1-phosphate uridylyltransferase (GALT), an enzyme needed for normal galactose metabolism. Without prompt treatment, affected newborns can develop life-threatening feeding intolerance, jaundice and liver disease, infection, and cataracts. GeneReviews: Classic Galactosemia (ncbi.nlm.nih.gov)

Newborn screening and immediate, lifelong restriction of lactose and high-galactose foods prevent most acute neonatal deaths, but they do not eliminate galactose made inside the body. Many people with CG therefore develop variable long-term problems affecting speech and language, learning, movement, behavior, bone health, and—in most affected females—ovarian function and fertility. There is currently no approved therapy that restores GALT activity or cures classic galactosemia. ACTION-Galactosemia Kids results (pmc.ncbi.nlm.nih.gov)

Scope of Recent Research (2020–present)

Research since 2020 has been active but remains small relative to more common genetic diseases. The central questions are whether restoring GALT in the liver and other affected tissues can prevent disease, whether reducing toxic galactose by-products can improve established complications, and when treatment must begin to protect the brain and ovaries. The field has produced compelling animal and cell-model results for gene replacement and messenger RNA (mRNA) therapy, but no restorative therapy has yet reached human clinical trials; the only advanced human drug program, govorestat, aims to reduce a by-product rather than correct the defective gene. Treatment landscape review (onlinelibrary.wiley.com)

Major Breakthroughs and Emerging Therapies

Gene replacement therapy is the most direct potential cure strategy. It uses an adeno-associated virus (AAV), a modified viral delivery vehicle, to supply a working copy of GALT. In a GALT-null rat model, a single neonatal AAV9-GALT treatment substantially lowered galactose metabolites in blood, liver, and brain, reduced cataracts, and produced metabolic and physical improvements lasting into early adulthood. Neonatal AAV9-GALT in rats (pmc.ncbi.nlm.nih.gov) In complementary work, AAV-delivered GALT restored enzyme activity and corrected abnormal galactose metabolism, oxidative stress, and endoplasmic-reticulum stress in patient-derived fibroblasts, with initial proof of concept in GALT-knockout mice. AAV-GALT in patient fibroblasts and mice (pubmed.ncbi.nlm.nih.gov)

mRNA replacement therapy is a potentially repeatable alternative to viral gene delivery. Lipid nanoparticles can carry laboratory-made GALT mRNA into cells, where it directs temporary production of GALT enzyme without altering genomic DNA. In GALT-deficient mice, repeated intravenous dosing reduced galactose-1-phosphate in liver, red blood cells, ovaries, and brain and lowered circulating galactose by more than 60%; a single neonatal dose also improved galactose sensitivity and growth. GALT mRNA therapy in mice (pmc.ncbi.nlm.nih.gov) A zebrafish study subsequently showed that lipid-nanoparticle-packaged human GALT mRNA could produce functional enzyme and lower disease-associated metabolites without observed toxicity in that model. GALT mRNA therapy in zebrafish (pmc.ncbi.nlm.nih.gov)

Substrate reduction and small-molecule approaches seek to lower harmful metabolites without replacing GALT. One approach inhibits galactokinase 1 (GALK1), the upstream enzyme that converts galactose into galactose-1-phosphate. Researchers have identified allosteric GALK1 inhibitors—molecules that act at a regulatory rather than catalytic site—and improved them to sub-100-nanomolar biochemical potency; genetic mouse studies further showed that GALK1 is the principal source of elevated galactose-1-phosphate in GALT-deficient liver and brain. GALK1 inhibitor optimization (pubmed.ncbi.nlm.nih.gov) GALK1 in GALT-deficient mice (pmc.ncbi.nlm.nih.gov)

A second small-molecule approach is pharmacological chaperoning: stabilizing certain misshapen mutant GALT proteins so that they retain more activity. A 2025 repurposing and laboratory-screening study found two candidate chaperones that increased activity of mutant GALT in vitro and reduced galactose-1-phosphate accumulation in patient fibroblasts. These findings are preliminary and would only be relevant for patients whose mutations leave some rescuable GALT protein. Pharmacochaperones for mutant GALT (pmc.ncbi.nlm.nih.gov)

Protein delivery and tissue-targeted nonviral gene delivery remain early experimental concepts. A 2025 review describes virus-like particles that delivered GALT protein into cultured fibroblast, liver, and kidney cells, and a separate NIH-supported program is developing nanoparticles carrying episomal—that is, non-integrating—GALT DNA to ovarian granulosa cells, with the goal of preventing fertility impairment. Treatment landscape review (onlinelibrary.wiley.com) NIH-supported ovarian gene-therapy project (govtribe.com)

Clinical Trials and Experimental Approaches

The leading clinical program has been govorestat (AT-007), an oral, brain-penetrant inhibitor of aldose reductase developed by Applied Therapeutics. Rather than restoring GALT, it aims to prevent conversion of galactose into galactitol. The Phase 3 ACTION-Galactosemia Kids study enrolled 47 children aged 2–17 years and randomized them 2:1 to govorestat or placebo for 18 months. The peer-reviewed report described rapid, sustained galactitol reduction and favorable results on several behavior, daily-living, cognition, tremor, and fine-motor measures, while speech and gross-motor outcomes did not show a treatment advantage. ACTION-Galactosemia Kids results (pmc.ncbi.nlm.nih.gov)

However, this program is not an approved treatment. On November 27, 2024, the U.S. Food and Drug Administration issued a Complete Response Letter for govorestat’s application, citing major data-quality concerns, failure of prespecified primary efficacy analyses to demonstrate statistically significant benefit, and insufficient evidence that plasma galactitol is a surrogate likely to predict clinical benefit. The FDA requested at least one new, adequate, well-controlled trial with clinically meaningful endpoints. FDA Complete Response Letter for govorestat (download.open.fda.gov) An adult open-label extension study, sponsored by Applied Therapeutics, has evaluated long-term safety, pharmacokinetics, and galactitol lowering in adults who previously participated in an earlier study, but its registry record lists no posted results. Adult AT-007 extension trial (clinicaltrials.gov)

No human interventional trial of AAV-GALT, mRNA-GALT, gene editing, GALK1 inhibition, or protein replacement for classic galactosemia was identified in the recent clinical literature reviewed for this report. These potential disease-correcting approaches remain preclinical. Treatment landscape review (onlinelibrary.wiley.com)

Methodologies and Scientific Approaches

Researchers use complementary disease models because no single model captures every human complication. Patient fibroblasts test restoration of GALT activity and cell stress; GALT-null mice and rats allow study of systemic metabolite correction, neonatal toxicity, cataracts, fertility, and movement; zebrafish offer a rapid way to examine development and ovarian biology. AAV-GALT in patient fibroblasts and mice (pubmed.ncbi.nlm.nih.gov) GALT mRNA therapy in mice (pmc.ncbi.nlm.nih.gov) GALT mRNA therapy in zebrafish (pmc.ncbi.nlm.nih.gov)

Key measurements include GALT enzyme activity, galactose-1-phosphate in red blood cells and tissues, blood galactose and galactitol, cataracts, fertility measures, motor function, and behavioral or cognitive testing. Researchers are also using RNA sequencing, single-cell RNA sequencing, tissue histology, and metabolomics to identify when ovarian injury begins and which cells must be reached by treatment. NIH-supported ovarian gene-therapy project (govtribe.com)

Leading Institutions and Funding

Major academic contributors include the University of Utah, Maastricht University, Emory University, the University of Michigan, Children’s Hospital Colorado, and investigators affiliated with the international Galactosemia Network. University of Utah investigators have led important GALT mRNA, GALK1-inhibition, animal-model, and ovarian-targeted gene-delivery work; Moderna collaborated on the early mouse mRNA study, while Pfizer scientists reported AAV-GALT studies in patient cells and mice. GALT mRNA therapy in mice (pmc.ncbi.nlm.nih.gov) AAV-GALT in patient fibroblasts and mice (pubmed.ncbi.nlm.nih.gov)

The National Institutes of Health’s Eunice Kennedy Shriver National Institute of Child Health and Human Development supported a University of Utah ovarian-targeted gene-therapy project with $425,071 obligated as of July 2025, including subawards involving Boston Children’s Hospital, Case Western Reserve University/Cleveland Clinic, and Maastricht University. NIH-supported ovarian gene-therapy project (govtribe.com) The patient-led Galactosemia Foundation reports awarding more than $931,595 in galactosemia research funding; its 2021 awards included $50,000 for improved gene therapy in a rat model and $48,457 for a “Marching towards a cure” project, while 2023 awards supported brain-metabolomics and experimental-treatment projects. Galactosemia Foundation funded research (galactosemia.org)

Strengths, Limitations, and Challenges

The strongest evidence for a potential cure is that GALT restoration can correct fundamental biochemical defects in multiple preclinical systems. AAV gene replacement may provide long-lived expression after one dose, while mRNA could allow adjustable repeat dosing without inserting DNA into the genome. Yet both approaches must demonstrate safe, durable delivery to the liver and, critically, sufficient correction of brain and ovarian disease; lipid nanoparticles tend to favor the liver, and AAV can provoke immune responses that may complicate repeat dosing. Treatment landscape review (onlinelibrary.wiley.com)

The govorestat experience also illustrates a central difficulty: lowering a biochemical marker is not the same as proving meaningful long-term improvement for patients. Although the pediatric publication reported favorable findings in several domains, U.S. and European regulators concluded that the evidence did not establish clear, consistent clinical benefit and questioned whether galactitol reduction reliably predicts improvement. ACTION-Galactosemia Kids results (pmc.ncbi.nlm.nih.gov) FDA Complete Response Letter for govorestat (download.open.fda.gov) EMA assessment of govorestat withdrawal (ema.europa.eu) Small patient populations, slow and variable disease progression, uncertain surrogate biomarkers, the need for childhood or neonatal intervention, and future treatment cost and access will all make definitive trials challenging.

Outlook and Future Directions

As of October 16, 2026, a cure for classic galactosemia is not close enough to forecast a near-term clinical arrival, but the field has moved beyond diet-only research toward plausible molecular correction. The most important milestones to watch are an investigational-new-drug application and first-in-human study for GALT replacement; evidence that liver-directed treatment protects the brain and ovaries; reproducible, clinically meaningful endpoints for trials; and a redesigned govorestat study, if pursued, that directly addresses the FDA’s concerns. Until then, AAV and mRNA GALT restoration are the clearest curative concepts, but remain promising preclinical programs rather than available therapies. Treatment landscape review (onlinelibrary.wiley.com)

References

Don't see your disease? Request a report